Bailard’s Capricor Therapeutics CAPR Stock Holding History

Bailard’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-33,601	Closed	-$202K	–	718
2022 Q3	$202K	Buy	33,601 +3,800	+13%	+$19.4K	0.01%	602
2022 Q2	$104K	Buy	+29,801	New	+$106K	﹤0.01%	650

Other funds holding CAPR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Bailard's CAPR Position: Q4 2022 in Review

Bailard sold out of Capricor Therapeutics (CAPR) in Q4 2022, closing a stake of 33,601 shares — an estimated $202K sold.

Bailard first reported a position in CAPR in Q2 2022 and held it in 2 quarters. The position peaked at $202K in Q3 2022. 31 funds tracked by Wall St. Rank hold CAPR as of Q4 2022.

Bailard reported no remaining Capricor Therapeutics position as of Q4 2022 after selling out during the quarter.
Bailard sold 33,601 Capricor Therapeutics shares in Q4 2022, an estimated $202K.
Bailard first reported a position in Capricor Therapeutics in Q2 2022 and held it in 2 quarters.
Bailard's Capricor Therapeutics position peaked at $202K in Q3 2022.
31 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.